Interphotoreceptor Retinoid Binding Protein Fragment IRBP

Modify Date: 2024-01-05 18:25:12

Interphotoreceptor Retinoid Binding Protein Fragment IRBP structure	Common Name	Interphotoreceptor Retinoid Binding Protein Fragment IRBP
	CAS Number	211426-18-5	Molecular Weight	2209.50
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₀₃H₁₅₇N₂₅O₂₉	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Interphotoreceptor Retinoid Binding Protein Fragment IRBP

Interphotoreceptor Retinoid Binding Protein Fragment (IRBP), a 20-residue peptide and a major pathogenic epitope, is present in the first homologous repeat of the interphotoreceptor retinoid binding protein peptide (IRBP 161–180), which can induce posterior uveitis (EAU)[1].

Name	Interphotoreceptor Retinoid Binding Protein Fragment IRBP

Description	Interphotoreceptor Retinoid Binding Protein Fragment (IRBP), a 20-residue peptide and a major pathogenic epitope, is present in the first homologous repeat of the interphotoreceptor retinoid binding protein peptide (IRBP 161–180), which can induce posterior uveitis (EAU)[1].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
References	[1]. Tang J, et al. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signatureand is driven by unique effector mechanisms: initial encounter with autoantigen defines diseasephenotype. J Immunol. 2007 May 1;178(9):5578-87. [2]. Cortes LM, et al. Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinalautoimmunity by inducing type 2 and regulatory T cells. J Leukoc Biol. 2008 Aug;84(2):577-85. [3]. Yang H, et al. Activation of liver X receptor alleviates ocular inflammation in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2014 Apr 28;55(4):2795-804.

Description

Related Catalog

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

References

[1]. Tang J, et al. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signatureand is driven by unique effector mechanisms: initial encounter with autoantigen defines diseasephenotype. J Immunol. 2007 May 1;178(9):5578-87.

[2]. Cortes LM, et al. Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinalautoimmunity by inducing type 2 and regulatory T cells. J Leukoc Biol. 2008 Aug;84(2):577-85.

[3]. Yang H, et al. Activation of liver X receptor alleviates ocular inflammation in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2014 Apr 28;55(4):2795-804.